BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 34660853)

  • 1. Burosumab treatment in a child with cutaneous skeletal hypophosphatemia syndrome: A case report.
    Khadora M; Mughal MZ
    Bone Rep; 2021 Dec; 15():101138. PubMed ID: 34660853
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The efficacy and safety of burosumab in two patients with cutaneous skeletal hypophosphatemia syndrome.
    Sugarman J; Maruri A; Hamilton DJ; Tabatabai L; Luca D; Cimms T; Krolczyk S; Roberts MS; Carpenter TO
    Bone; 2023 Jan; 166():116598. PubMed ID: 36341949
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Burosumab for the treatment of cutaneous-skeletal hypophosphatemia syndrome.
    Abebe L; Phung K; Robinson ME; Waldner R; Carsen S; Smit K; Tice A; Lazier J; Armour C; Page M; Dover S; Rauch F; Koujok K; Ward LM
    Bone Rep; 2024 Mar; 20():101725. PubMed ID: 38229908
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A Case Report: First Long-Term Treatment With Burosumab in a Patient With Cutaneous-Skeletal Hypophosphatemia Syndrome.
    Merz LM; Buerger F; Ziegelasch N; Zenker M; Wieland I; Lipek T; Wallborn T; Terliesner N; Prenzel F; Siekmeyer M; Dittrich K
    Front Endocrinol (Lausanne); 2022; 13():866831. PubMed ID: 35600592
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cutaneous skeletal hypophosphatemia syndrome (CSHS) is a multilineage somatic mosaic RASopathy.
    Lim YH; Ovejero D; Derrick KM; ; Collins MT; Choate KA
    J Am Acad Dermatol; 2016 Aug; 75(2):420-7. PubMed ID: 27444071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cutaneous skeletal hypophosphatemia syndrome: clinical spectrum, natural history, and treatment.
    Ovejero D; Lim YH; Boyce AM; Gafni RI; McCarthy E; Nguyen TA; Eichenfield LF; DeKlotz CM; Guthrie LC; Tosi LL; Thornton PS; Choate KA; Collins MT
    Osteoporos Int; 2016 Dec; 27(12):3615-3626. PubMed ID: 27497815
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New Therapies for Hypophosphatemia-Related to FGF23 Excess.
    Athonvarangkul D; Insogna KL
    Calcif Tissue Int; 2021 Jan; 108(1):143-157. PubMed ID: 32504139
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Burosumab vs Phosphate/Active Vitamin D in Pediatric X-Linked Hypophosphatemia: A Subgroup Analysis by Dose Level.
    Imel EA; Glorieux FH; Whyte MP; Portale AA; Munns CF; Nilsson O; Simmons JH; Padidela R; Namba N; Cheong HI; Pitukcheewanont P; Sochett E; Högler W; Muroya K; Tanaka H; Gottesman GS; Biggin A; Perwad F; Chen A; Roberts MS; Ward LM
    J Clin Endocrinol Metab; 2023 Oct; 108(11):2990-2998. PubMed ID: 37084401
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A case report to assess the safety and efficacy of Burosumab, an investigational antibody to FGF23, in a single pediatric patient with Epidermal Nevus Syndrome and associated hypophosphatemic rickets.
    Huynh C; Gillis A; Fazendin J; Abdullatif H
    Bone Rep; 2022 Dec; 17():101605. PubMed ID: 35899095
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burosumab treatment for fibrous dysplasia.
    Gladding A; Szymczuk V; Auble BA; Boyce AM
    Bone; 2021 Sep; 150():116004. PubMed ID: 33984553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Improvement in the mobility of a patient with fibroblast growth factor 23-related hypophosphatemic osteomalacia and decompensated liver cirrhosis in response to burosumab: a case report.
    Toi N; Imanishi Y; Nagata Y; Kurajoh M; Morioka T; Shoji T; Shinto Y; Emoto M
    Endocr J; 2023 Apr; 70(4):419-426. PubMed ID: 36575021
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized, Double-Blind, Placebo-Controlled, Phase 3 Trial Evaluating the Efficacy of Burosumab, an Anti-FGF23 Antibody, in Adults With X-Linked Hypophosphatemia: Week 24 Primary Analysis.
    Insogna KL; Briot K; Imel EA; Kamenický P; Ruppe MD; Portale AA; Weber T; Pitukcheewanont P; Cheong HI; Jan de Beur S; Imanishi Y; Ito N; Lachmann RH; Tanaka H; Perwad F; Zhang L; Chen CY; Theodore-Oklota C; Mealiffe M; San Martin J; Carpenter TO;
    J Bone Miner Res; 2018 Aug; 33(8):1383-1393. PubMed ID: 29947083
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Interim Analysis of a Phase 2 Open-Label Trial Assessing Burosumab Efficacy and Safety in Patients With Tumor-Induced Osteomalacia.
    Imanishi Y; Ito N; Rhee Y; Takeuchi Y; Shin CS; Takahashi Y; Onuma H; Kojima M; Kanematsu M; Kanda H; Seino Y; Fukumoto S
    J Bone Miner Res; 2021 Feb; 36(2):262-270. PubMed ID: 32967046
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Burosumab in X-linked hypophosphatemia and perspective for chronic kidney disease.
    Balani S; Perwad F
    Curr Opin Nephrol Hypertens; 2020 Sep; 29(5):531-536. PubMed ID: 32701599
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dramatic Transformation After Burosumab in a Young Boy With X-linked Hypophosphatemia: A Life-Changing Saga.
    Baradhi K
    Cureus; 2022 Feb; 14(2):e22340. PubMed ID: 35371638
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Burosumab: Current status and future prospects.
    Goyal A; Tandon N
    Best Pract Res Clin Endocrinol Metab; 2024 Mar; 38(2):101826. PubMed ID: 37858479
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Burosumab for the Treatment of Tumor-Induced Osteomalacia.
    Jan de Beur SM; Miller PD; Weber TJ; Peacock M; Insogna K; Kumar R; Rauch F; Luca D; Cimms T; Roberts MS; San Martin J; Carpenter TO
    J Bone Miner Res; 2021 Apr; 36(4):627-635. PubMed ID: 33338281
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cutaneous Skeletal Hypophosphatemia Syndrome in Association with a Mosaic
    Park PG; Park E; Hyun HS; Kang HG; Ha IS; Cho TJ; Ko JM; Cheong HI
    Ann Clin Lab Sci; 2018 Sep; 48(5):665-669. PubMed ID: 30373874
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Burosumab Therapy in Children with X-Linked Hypophosphatemia.
    Carpenter TO; Whyte MP; Imel EA; Boot AM; Högler W; Linglart A; Padidela R; Van't Hoff W; Mao M; Chen CY; Skrinar A; Kakkis E; San Martin J; Portale AA
    N Engl J Med; 2018 May; 378(21):1987-1998. PubMed ID: 29791829
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effect of Burosumab Compared With Conventional Therapy on Younger vs Older Children With X-linked Hypophosphatemia.
    Ward LM; Glorieux FH; Whyte MP; Munns CF; Portale AA; Högler W; Simmons JH; Gottesman GS; Padidela R; Namba N; Cheong HI; Nilsson O; Mao M; Chen A; Skrinar A; Roberts MS; Imel EA
    J Clin Endocrinol Metab; 2022 Jul; 107(8):e3241-e3253. PubMed ID: 35533340
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.